BY NOKUTHABA DLAMINI

A 43-year-old Tsholotsho man, Ezekiel Ndlovu, has been convicted on two counts of threatening violence and one count of assault after a series of violent incidents at a local homestead earlier this month.

According to the National Prosecuting Authority, the offences occurred on the 10th 10 and 15 November, at Soluswe line. During a misunderstanding while socializing, Ndlovu reportedly threatened to kill a male victim using an axe. Five days later, he allegedly returned to the same homestead and again issued threats — this time targeting the owner of the property.

In a separate incident at the same gathering, Ndlovu struck another man on the left leg with an iron bar, causing bodily harm.

He was sentenced to 12 months in jail after being convicted at the Tsholotsho Magistrates’ Court.

BY WANDILE TSHUMA

Zimbabwe has taken a major step in the fight against HIV following the rapid approval of Lenacapavir, a groundbreaking long-acting injectable for HIV pre-exposure prophylaxis (PrEP). The Medicines Control Authority of Zimbabwe (MCAZ) authorised the drug in just 23 days, marking one of the fastest regulatory approvals in the country’s history.

The application, submitted by pharmaceutical company Gilead Sciences in October, underwent an expedited review because of its public health importance. MCAZ says the fast-tracked process did not compromise scientific scrutiny, with the product subjected to a rigorous assessment of its safety, efficacy and quality.

Lenacapavir is designed for adults and adolescents weighing at least 35kg who are HIV-negative but at substantial risk of infection. Unlike traditional daily oral PrEP, the medicine is administered as a six-monthly injection, following an initiation phase that includes one injection and oral tablets on Days 1 and 2. Health authorities say this long-acting formulation could dramatically improve adherence and expand prevention options, particularly for communities where daily pill-taking is difficult.

MCAZ Director-General  Richard T. Rukwata described the approval as a landmark moment in Zimbabwe’s HIV response.

“The rapid approval of Lenacapavir reflects MCAZ’s dedication to accelerating access to trusted, high-quality health products. This milestone brings new hope for HIV prevention and reinforces our commitment to safeguarding public health,” he said.

To fast-track the process, the Authority applied a regulatory reliance approach, drawing on scientific assessments from the World Health Organization’s Prequalification Programme (WHO PQ). This allowed evaluators to build on internationally recognised review processes while ensuring Zimbabwe’s own standards were met.

The introduction of Lenacapavir comes as Zimbabwe continues efforts to reduce new HIV infections, particularly among young people and key populations who face barriers to consistent PrEP use. Public health experts say the drug’s twice-yearly dosing could be a game changer in improving uptake and protection.

MCAZ says it remains committed to ensuring Zimbabweans have access to safe, effective and good-quality medical products, in line with its mandate under the Medicines and Allied Substances Control Act.

BY WANDILE TSHUMA

The World Health Organization (WHO) data show that Zimbabwe continues to make measurable gains in its fight against tuberculosis (TB).

According to the Global Tuberculosis Report 2025, Zimbabwe’s estimated TB incidence has declined to 203 per 100,000 population, representing a 3.8 % reduction from 2023. The report states that “TB incidence in Zimbabwe has fallen to 203 per 100 000, a 3.8 % reduction from 2023.” 

On treatment outcomes, the country’s overall success rate for all forms of TB has improved to 91 %, up from 89 % in 2023. The report quotes: “Treatment success for all forms of TB has improved to 91 %, up from 89 % in 2023.” 

For drug-resistant TB (DR-TB), progress has also been recorded: treatment success rose from 64 % for the 2021 cohort to 68 % for the 2022 cohort. As the report notes: “treatment success for drug-resistant TB increased from 64 % for the 2021 cohort to 68 % for the 2022 cohort.” 

In the critical sphere of TB‐HIV co-infection, Zimbabwe saw a drop in the co‐infection rate to 49 %, down from 51 %. The report states: “TB/HIV co-infection rates have fallen to 49 %, down from 51 %.” 

Zooming out, the 2025 global report shows that across the world TB is falling again, although not yet at the pace required to meet targets. Globally, incidence declined by almost 2 % between 2023 and 2024, and deaths fell around 3 %. 

However, the report warns that progress is fragile. Funding shortfalls, health-system disruptions (especially during the COVID-19 era), and the ongoing challenge of drug-resistant TB threaten to erode gains. The WHO page reminds that the 2025 edition “provides a comprehensive … assessment of the TB epidemic … at global, regional and country levels.” 

For example, although more people are being diagnosed and treated than in previous years, not enough are being reached with preventive interventions, and many countries are still far from the targets set under the End TB Strategy.